MXPA02006034A - Formas de dosis mucosaloral de apomorfina. - Google Patents
Formas de dosis mucosaloral de apomorfina.Info
- Publication number
- MXPA02006034A MXPA02006034A MXPA02006034A MXPA02006034A MXPA02006034A MX PA02006034 A MXPA02006034 A MX PA02006034A MX PA02006034 A MXPA02006034 A MX PA02006034A MX PA02006034 A MXPA02006034 A MX PA02006034A MX PA02006034 A MXPA02006034 A MX PA02006034A
- Authority
- MX
- Mexico
- Prior art keywords
- apomorphine
- dextran
- weight
- oral mucosal
- formulation
- Prior art date
Links
- VMWNQDUVQKEIOC-CYBMUJFWSA-N apomorphine Chemical compound C([C@H]1N(C)CC2)C3=CC=C(O)C(O)=C3C3=C1C2=CC=C3 VMWNQDUVQKEIOC-CYBMUJFWSA-N 0.000 title abstract 3
- 229960004046 apomorphine Drugs 0.000 title abstract 3
- 239000002552 dosage form Substances 0.000 title 1
- 229920002307 Dextran Polymers 0.000 abstract 3
- 239000000203 mixture Substances 0.000 abstract 3
- 238000009472 formulation Methods 0.000 abstract 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 abstract 1
- 239000008108 microcrystalline cellulose Substances 0.000 abstract 1
- 229940016286 microcrystalline cellulose Drugs 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 230000002035 prolonged effect Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Psychology (AREA)
- Zoology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
Abstract
Una formulacion farmaceutica para la administracion mucosal oral de liberacion prolongada de apomorfina, la cual comprende una cantidad terapeuticamente efectiva de apomorfina o una sal farmaceuticamente aceptable o un pro-medicamento de la misma, en combinacion con un vehiculo que comprende de aproximadamente 10 por ciento en peso a aproximadamente 95 por ciento en peso de dextran, basado en el peso total de la formulacion. En una modalidad de la invencion, el dextran que tiene un peso molecular en un rango entre 5000 Daltones y 100,000 Daltones es el unico componente de la formulacion para la prolongacion de la liberacion del componente de medicamento activo. En una modalidad alternativa, una mezcla de celulosa microcristalina y dextran actua como componentes para prolongar la liberacion de apomorfina.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US47584499A | 1999-12-30 | 1999-12-30 | |
| PCT/US2000/034548 WO2001049292A1 (en) | 1999-12-30 | 2000-12-19 | Oral mucosal dosage forms of apomorphine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MXPA02006034A true MXPA02006034A (es) | 2004-08-23 |
Family
ID=23889387
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MXPA02006034A MXPA02006034A (es) | 1999-12-30 | 2000-12-19 | Formas de dosis mucosaloral de apomorfina. |
Country Status (14)
| Country | Link |
|---|---|
| EP (1) | EP1242088A1 (es) |
| JP (1) | JP2004501065A (es) |
| CN (1) | CN1414853A (es) |
| AU (1) | AU2440901A (es) |
| BR (1) | BR0012822A (es) |
| CA (1) | CA2394297A1 (es) |
| CZ (1) | CZ20022245A3 (es) |
| HK (1) | HK1051315A1 (es) |
| HU (1) | HUP0400495A3 (es) |
| IL (1) | IL150034A0 (es) |
| MX (1) | MXPA02006034A (es) |
| NO (1) | NO20023190L (es) |
| PL (1) | PL366204A1 (es) |
| WO (1) | WO2001049292A1 (es) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE0202365D0 (sv) | 2002-08-05 | 2002-08-05 | Pharmacia Ab | New formulation and use thereof |
| SE0302947D0 (sv) | 2003-01-24 | 2003-11-07 | Magle Ab | A composition material for transmucosal delivery |
| EA012306B1 (ru) * | 2003-01-24 | 2009-08-28 | Магле Холдинг Аб | Композиционный материал для доставки через слизистые оболочки |
| CA2562391A1 (en) * | 2004-04-14 | 2005-10-27 | Takeda Pharmaceutical Company Limited | Solid pharmaceutical preparation |
| GB0509317D0 (en) * | 2005-05-06 | 2005-06-15 | Clarke Anthony | Pharmaceutical formulation of apomorphine |
| FI2442650T4 (fi) * | 2009-06-12 | 2025-08-06 | Sunovion Pharmaceuticals Inc | Kielen alle annettava apomorfiini |
| US20220249465A1 (en) * | 2019-05-31 | 2022-08-11 | Primo Pharmatech Llc | Unit dosage form for transmucosal drug delivery of an active pharmaceutical ingredient |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK0865789T3 (da) * | 1993-03-26 | 2005-07-18 | Franciscus Wilhelmus He Merkus | Farmaceutiske præparater til intranasal administration af dihydroergotamin |
| GB9517062D0 (en) * | 1995-08-18 | 1995-10-25 | Scherer Ltd R P | Pharmaceutical compositions |
-
2000
- 2000-12-19 MX MXPA02006034A patent/MXPA02006034A/es unknown
- 2000-12-19 EP EP00988174A patent/EP1242088A1/en not_active Withdrawn
- 2000-12-19 WO PCT/US2000/034548 patent/WO2001049292A1/en not_active Ceased
- 2000-12-19 BR BR0012822-8A patent/BR0012822A/pt not_active IP Right Cessation
- 2000-12-19 CA CA002394297A patent/CA2394297A1/en not_active Abandoned
- 2000-12-19 IL IL15003400A patent/IL150034A0/xx unknown
- 2000-12-19 PL PL00366204A patent/PL366204A1/xx not_active Application Discontinuation
- 2000-12-19 CZ CZ20022245A patent/CZ20022245A3/cs unknown
- 2000-12-19 CN CN00818098A patent/CN1414853A/zh active Pending
- 2000-12-19 HU HU0400495A patent/HUP0400495A3/hu unknown
- 2000-12-19 JP JP2001549660A patent/JP2004501065A/ja not_active Withdrawn
- 2000-12-19 HK HK03101912.0A patent/HK1051315A1/zh unknown
- 2000-12-19 AU AU24409/01A patent/AU2440901A/en not_active Abandoned
-
2002
- 2002-07-01 NO NO20023190A patent/NO20023190L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| AU2440901A (en) | 2001-07-16 |
| NO20023190L (no) | 2002-08-29 |
| EP1242088A1 (en) | 2002-09-25 |
| JP2004501065A (ja) | 2004-01-15 |
| CA2394297A1 (en) | 2001-07-12 |
| NO20023190D0 (no) | 2002-07-01 |
| CZ20022245A3 (cs) | 2002-10-16 |
| WO2001049292A1 (en) | 2001-07-12 |
| IL150034A0 (en) | 2002-12-01 |
| HUP0400495A3 (en) | 2007-05-02 |
| PL366204A1 (en) | 2005-01-24 |
| BR0012822A (pt) | 2004-03-09 |
| CN1414853A (zh) | 2003-04-30 |
| HK1051315A1 (zh) | 2003-08-01 |
| HUP0400495A2 (hu) | 2004-06-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE424810T1 (de) | Ein hydrokolloid und einen celluloseether enthaltende tablette mit verzögerter freisetzung | |
| EA200200106A1 (ru) | Фармацевтическая композиция леводопа/карбидопа/энтакапон | |
| HUP0203870A2 (hu) | Adenozinreceptor agonistát vagy antagonistát tartalmazó gyógyászati készítmény | |
| EA200401009A1 (ru) | Предварительно желатинированный крахмал в композиции с контролируемым высвобождением | |
| NO20011502D0 (no) | Fentanylsammensetning for behandling av akutt smerte | |
| DK0954314T3 (da) | Doseringsformer til bedring af mandlig erektionsdefekt | |
| MY118371A (en) | Tetrahydrolipstatin containing compositions | |
| GEP20074208B (en) | Substituted amides active at the cannabinoid-1 receptor | |
| MX2007015480A (es) | Formulaciones de dosificacion solida de medicamentos narcoticos que tienen adsorcion bucal mejorada. | |
| BR0115965A (pt) | Composições farmacêuticas para a liberação oral de agentes farmacologicamente ativos | |
| WO2002015903A3 (de) | Neue pharmazeutische zusammensetzung zur verabreichung von n-0923 | |
| EA200400007A1 (ru) | ФАРМАЦЕВТИЧЕСКИЙ СОСТАВ ДЛЯ ЭФФЕКТИВНОГО ВВЕДЕНИЯ АПОМОРФИНА, 6aR-(-)-N-ПРОПИЛ-НОРАПОМОРФИНА, ИХ ПРОИЗВОДНЫХ И ИХ ПРОЛЕКАРСТВ | |
| SG147450A1 (en) | Sustained release pharmaceutical compositions comprising aplindore and derivatives thereof | |
| WO2008023016A3 (en) | Galenic formulations of aliskiren | |
| CA2360220A1 (en) | Oxadiazole compounds and compositions for delivering active agents | |
| AP1849A (en) | Dosage regimen and pharmaceutical composition for emergency contraception | |
| PT1608349E (pt) | Sistema de administração oral que compreende um agente antibacteriano e um agente anti-inflamatório | |
| PT975348E (pt) | Composicoes de tibolona estabilizadas | |
| MXPA02006034A (es) | Formas de dosis mucosaloral de apomorfina. | |
| CA2135179A1 (en) | Pharmaceutical Compositions of Alkylsulphonamides 5HT1 Agonists for Rectal Administration | |
| BE2016C017I2 (es) | ||
| WO2003070153A3 (en) | Stabilized pharmaceutical compositions of halofuginone and other quinazolinone derivatives | |
| TW200505504A (en) | Saquinavir mesylate oral dosage form | |
| MXPA01003340A (es) | Composiciones farmaceuticas en base a alfa-ciclodextrina para la administracion por via oral de analogos de lh-rh. | |
| HK1048770A1 (zh) | 组胺作为用於经粘膜或经皮传递的一种药物传递增强化合物的用途 |